Menu
Not yet recruiting NCT07102056

18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

— Observational Neuroendocrine Tumors

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 18F-AlF-NOTA-Octreotide PET-CT or PET-MR.
Who it may be relevant to
Registry conditions: Neuroendocrine Tumors. Basic parameters: 20 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms

Overview

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Interventions

  • Diagnostic test 18F-AlF-NOTA-Octreotide PET-CT or PET-MR
    18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Primary outcome measures

  • Diagnostic efficacy [Time frame: through study completion, an average of 1.5 year]

Eligibility criteria

Inclusion criteria

  • Clinical diagnosed of neuroendocrine neoplasms.
  • Suspected of neuroendocrine neoplasms.

Exclusion criteria

  • Inability to undergo biopsy/surgical treatment.
  • Concurrent active malignancy.
  • Severe uncontrolled comorbidities/active infections.
  • Inability to provide informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07102056 · FirstZhejiangU-18OC-NENs

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗